← 返回首页
亚洲 · 综合新闻 · The Straits Times

US FDA rejects closely watched lung cancer drug from China

来源:The Straits Times · 新加坡 22 分钟前
US FDA rejects closely watched lung cancer drug from China
The Straits Times

详细摘要

US FDA rejects closely watched lung cancer drug ivonescimab from China after trial failed to show a survival benefit. Read more at straitstimes.com.

The US Food and Drug Administration said the global clinical trial had not shown a statistically significant extension in patients’ lives.

The US Food and Drug Administration (FDA) rejected a first-of-its-kind cancer drug that was invented in China, a setback for a medicine that had become a symbol of China’s ascendance as a powerhouse in drug development.

Summit Therapeutics, the Florida company that has been seeking to bring the drug to the US market, disclosed the agency’s decision in a news release on Nov 15. Summit bought the US rights to the drug from Akeso Biopharma, a Chinese drugmaker that invented the drug in its laboratories and sells it in China.

文章开头,摘自The Straits Times。如需阅读全文,请前往媒体网站。

在 The Straits Times 阅读全文 登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.straitstimes.com)

推荐阅读